Georgia hasn't given EDE $20M, they have provided value equivalent to $20M. I have both EDE and AJX, what I am saying is that one is tightly controlled by the Soloman's, the other isn't. Both were at similar points in the coy development cycle, i.e. trial orders, small batches, proving technology but AJX's SP is moved a lot more by small vols (both up and down) than EDE is. Now I see AJX moving ahead in teh cycle due to sales picking up, although I expect EDE sales to start picking up soon as well.
Ann: Appendix 4C - quarterly-AJX.AX, page-116
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
